Oppenheimer & CO Inc Apellis Pharmaceuticals, Inc. Transaction History

Oppenheimer & CO Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$55.39 - $72.47 $483,554 - $632,663	-8,730 Reduced 71.38%	3,500 $205,000
Q4 2023 Feb 13, 2024	BUY	$37.14 - $64.82 $14,521 - $25,344	391 Added 3.3%	12,230 $732,000
Q3 2023 Nov 07, 2023	BUY	$23.65 - $89.22 $69,791 - $263,288	2,951 Added 33.2%	11,839 $450,000
Q2 2023 Aug 02, 2023	BUY	$76.68 - $93.31 $118,700 - $144,443	1,548 Added 21.09%	8,888 $809,000
Q1 2023 May 10, 2023	SELL	$46.59 - $66.96 $8,153 - $11,717	-175 Reduced 2.33%	7,340 $484,000
Q4 2022 Feb 07, 2023	BUY	$43.24 - $61.04 $5,707 - $8,057	132 Added 1.79%	7,515 $388,000
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $1,387 - $2,159	-31 Reduced 0.42%	7,383 $504,000
Q2 2022 Aug 08, 2022	BUY	$35.07 - $59.21 $1,928 - $3,256	55 Added 0.75%	7,414 $335,000
Q1 2022 May 12, 2022	BUY	$35.46 - $54.12 $260,950 - $398,269	7,359 New	7,359 $374,000
Q1 2021 May 10, 2021	SELL	$40.8 - $57.39 $174,093 - $244,883	-4,267 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$30.79 - $57.2 $97,973 - $182,010	-3,182 Reduced 42.72%	4,267 $244,000
Q3 2020 Nov 13, 2020	BUY	$25.89 - $33.65 $192,854 - $250,658	7,449 New	7,449 $225,000

300

111M

2.63M

845K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.